Dr. Oliver Sude

Oliver is a German qualified lawyer who works for over 25 years with the life sciences industry focusing on EU regulatory affairs, intellectual property and market access issues. He is providing strategic advice in policy matters at EU and Member States level.

Oliver has been a key driver in setting up a major pharmaceutical industry association at the EU level by building public affairs and policy capabilities for the organization.

With his longstanding experience in EU policy, Oliver is focusing on matters like the General Pharmaceutical Legislation and various other EU legislative procedures, representing industry needs in these processes but also by providing policy roadmaps and by organizing an effective stakeholder engagement for biopharmaceutical companies.

Matias Olsen

Matias has over 8 years’ experience advising biopharmaceutical companies in policy, market access and reimbursement matters. With a particular focus on the EU Health Technology Assessment (EU HTA) he supports navigating various companies in navigating this new process.

Matias also has extensive expertise in the field of genomics and oncology matters by creating industry coalitions in both areas. Previously he has been working with the European Cancer Patient Coalition (ECPC) and the Norwegian Social Security Administration focusing on reimbursement of medical devices and coordination of social security within the EU/EEA.

Matias also covers market access for advanced diagnostics and use of Real-World Evidence by payers and HTA bodies and is following other current legislative initiatives such as the revision of the General Pharmaceutical Legislation and Europe’s Beating Cancer Plan.